Beta 1 Blockers
Beta 1 Blockers - Related Videos
01:17
Antihypertensive Drugs: Action of β1 Blockers
0 Views •
2024
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
03:16
Intravenous Delivery of Receptor Blockers to Reduce Brain Edema in a Mouse Model
0 Views •
2025
Source: Zeynalov, E. et. al., Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema. J. Vis. Exp. (2016)This video demonstrates the intravenous delivery of an arginine-vasopressin (AVP) receptor antagonist in a mouse model. Transient middle cerebral artery occlusion induces brain edema. An AVP receptor antagonist is administered through a catheter in the left jugular vein, alleviating edema.
02:08
Assessing Muscle Contraction with Neuromuscular Blocker Treatment
0 Views •
2025
This video demonstrates assessing the muscle using cultured motor neurons, Schwann cells, and myotubes, followed by treatment with a neuromuscular blocker to inhibit contraction. Color-coded time-motion graphics show a color-coded time-motion graphic. Red indicates the fastest movement, and blue indicates the slowest.
08:53
Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
0 Views •
2025
Here, we present a systematic method describing the quasi-reversible self-assembly of the amyloid beta 1-40 (Aβ1-40)-coated 20 nm gold aggregates. The nano-size-dependent quasi-reversible networking between peptides was correlated with specific amino acids or sections of the Aβ1-40 monomer.
FAQs
Blocking beta 1 adrenergic receptors prevents catecholamine-driven activation of cyclic AMP signaling in cardiac tissue. This produces several coordinated effects: heart rate falls, myocardial contractility decreases, and atrioventricular conduction slows. Because these changes affect cardiac activity through separate functional outputs, beta 1 blockers can influence rhythm control and the heart’s response to sympathetic stimulation rather than only reducing pulse rate.
Cyclic AMP carries intracellular signals generated after beta 1 receptor activation. When beta 1 blockers interrupt this pathway, cardiac cells receive less stimulatory input from catecholamines such as epinephrine. The resulting decrease in rate, contractility, and atrioventricular conduction explains how receptor antagonism translates into clinically relevant cardiovascular effects.
Relative beta 1 selectivity favors effects in cardiac tissue over effects mediated by beta 2 receptors in the airways and peripheral vasculature. This distinction can help limit unwanted beta 2 receptor effects, but selectivity is not absolute. It varies among individual drugs and may diminish as the dose increases, making dose and drug choice important pharmacologic considerations.
Beta 1 receptors in the kidneys regulate renin release during sympathetic stimulation. Blocking them suppresses this renin response, adding a renal mechanism to the direct cardiac effects of beta 1 antagonism. This matters because the overall cardiovascular action is not produced solely within the heart; kidney-mediated signaling also contributes to the pharmacologic rationale for their use in hypertension.
In pharmacology, beta 1 blockers are used for hypertension, angina, selected cardiac arrhythmias, and some forms of heart failure. Their therapeutic effects reflect different combinations of reduced heart rate, lower myocardial contractility, slower atrioventricular conduction, and suppressed renin release. The appropriate clinical context depends on the cardiovascular problem and the specific response that needs to be moderated.
Slowing atrioventricular conduction is a key reason beta 1 blockade can be relevant to selected cardiac arrhythmias. By reducing catecholamine-mediated signaling, these medicines also lower heart rate and cardiac stimulation. Their usefulness therefore depends on whether moderating sympathetic effects and conduction is appropriate for the rhythm problem, rather than treating every arrhythmia through the same mechanism.
Comparisons should account for both drug-specific selectivity and dose. Two beta 1 blockers may differ in how strongly they limit beta 2 receptor effects, while increasing the dose can reduce the practical separation between beta 1 and beta 2 actions. Pharmacologic interpretation therefore requires attention to the medicine used, exposure level, target cardiovascular effect, and potential noncardiac receptor effects.